Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TECX 
Tectonic Therapeutic, Inc. (TECX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: TECX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $79.71
1 Year Target Price $79.71
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 172.23% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 477.91M USD | Price to earnings Ratio 6.17 | 1Y Target Price 79.71 |
Price to earnings Ratio 6.17 | 1Y Target Price 79.71 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.70 - 61.07 | Updated Date 08/30/2025 |
52 Weeks Range 13.70 - 61.07 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.14 |
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -1.32 | Actual -1.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.97% | Return on Equity (TTM) -29.32% |
Valuation
Trailing PE 6.17 | Forward PE - | Enterprise Value 192469749 | Price to Sales(TTM) - |
Enterprise Value 192469749 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18712100 | Shares Floating 9741908 |
Shares Outstanding 18712100 | Shares Floating 9741908 | ||
Percent Insiders 38.21 | Percent Institutions 65 |
Upturn AI SWOT
Tectonic Therapeutic, Inc.
Company Overview
History and Background
Tectonic Therapeutic, Inc. is a biopharmaceutical company focusing on GPCR-targeted therapeutics. While specific founding details are not publicly available, it operates in the rapidly evolving field of drug discovery targeting G protein-coupled receptors (GPCRs).
Core Business Areas
- GPCR-targeted drug discovery: Developing novel therapeutics that selectively target GPCRs, aiming to unlock new treatments for various diseases.
- Structure-based drug design: Utilizing structural biology to design and optimize drug candidates with improved efficacy and safety.
- Therapeutic Programs: Developing a pipeline of therapeutic programs targeting specific GPCRs and indications.
Leadership and Structure
Details on the specific leadership team and organizational structure are not readily available from public sources but would include a typical structure: CEO, CSO, CFO, and heads of research, development, and operations.
Top Products and Market Share
Key Offerings
- Pipeline of GPCR-targeted therapeutics: Tectonic Therapeutic, Inc. is focused on developing therapeutics against GPCRs. Specific market share data for pipeline programs is not available. Competitors include major pharmaceutical companies and other biotech companies that also develop GPCR-targeted therapies. This includes companies like Amgen (AMGN), Novo Nordisk (NVO), and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in GPCR-targeted therapeutics, is characterized by intense competition, high R&D costs, and a stringent regulatory environment.
Positioning
Tectonic Therapeutic, Inc. aims to be a leader in GPCR-targeted drug discovery through its innovative approach and structural insights.
Total Addressable Market (TAM)
The GPCR-targeted therapeutics market is estimated to be in the billions of dollars. Tectonic Therapeutic, Inc.'s position relative to this TAM depends on the success of its pipeline programs.
Upturn SWOT Analysis
Strengths
- GPCR-targeting expertise
- Structure-based drug design platform
- Innovative therapeutic approach
Weaknesses
- Early-stage pipeline
- Limited financial resources relative to larger pharma companies
- Reliance on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery or acquisitions
- Advancements in structural biology and drug design technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- AMGN
- NVO
- LLY
Competitive Landscape
Tectonic Therapeutic, Inc. competes with larger pharmaceutical companies that have greater resources but aims to differentiate itself through its focus on structure-based design and GPCR expertise. Its advantages lie in a targeted approach, while disadvantages exist in resources.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to lack of public data.
Future Projections: Future growth depends on successful pipeline development and potential partnerships.
Recent Initiatives: Recent initiatives likely include advancing pipeline programs, securing funding, and forming strategic collaborations.
Summary
Tectonic Therapeutic, Inc. is a biotech company focusing on a promising area of drug discovery with GPCR targets. It has strong potential given its approach, but it is an early-stage company and subject to significant risks associated with drug development, particularly clinical trial success and funding. They will need strong partnership to compete with larger players in the market. Their scientific approach is a strength but their small size is a limitation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- Industry Reports
- Third-Party Market Research
Disclaimers:
The information provided is based on publicly available data and may not be entirely accurate. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://tectonictx.com |
Full time employees 51 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.